Vanda faces setback in FDA approval of schizophrenia drug

07/28/2008 | American City Business Journals · Bloomberg

The FDA sent a "not approvable" letter to Vanda Pharmaceuticals for iloperidone and asked for more studies to compare the efficacy of the schizophrenia-drug candidate with rivals such as Johnson & Johnson's Risperdal and Eli Lilly and Co.'s Zyprexa. Vanda plans to discuss the decision with the agency, which also requested more safety data on the long-term effects of the drug when taken in 20 mg to 24 mg doses.

View Full Article in:

American City Business Journals · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Actuary
NTA Life
Addison, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA